A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients

Xiao, Xi; Li, Jianpeng; Wan, Shun; Wu, Mingzhe; Li, Zonglin; Tian, Junqiang; Mi, Jun

doi:10.3389/fgene.2022.1006151

Cited by 9 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 2011 to 2016, only a meager 32.3% 5-year survival rate was observed in the United States for advanced-stage prostate cancer. 14,15 Therefore, it is crucial to promptly identify innovative prognostic for PCa in order to improve the accuracy of therapy and healthcare management.…”

Section: Discussionmentioning

confidence: 99%

FOXS1 acts as an oncogene and induces EMT through FAK/PI3K/AKT pathway by upregulating HILPDA in prostate cancer

Ren,

Wang,

et al. 2024

The FASEB Journal

View full text Add to dashboard Cite

Prostate cancer (PCa) is a widespread global health concern characterized by elevated rates of occurrence, and there is a need for novel therapeutic targets to enhance patient outcomes. FOXS1 is closely linked to different cancers, but its function in PCa is still unknown. The expression of FOXS1, its prognostic role, clinical significance in PCa, and the potential mechanism by which FOXS1 affects PCa progression were investigated through bioinformatics analysis utilizing public data. The levels of FOXS1 and HILPDA were evaluated in clinical PCa samples using various methods, such as western blotting, immunohistochemistry, and qRT‐PCR. To examine the function and molecular mechanisms of FOXS1 in PCa, a combination of experimental techniques including CCK‐8 assay, flow cytometry, wound‐healing assay, Transwell assay, and Co‐IP assay were employed. The FOXS1 expression levels were significantly raised in PCa, correlating strongly with tumor aggressiveness and an unfavorable prognosis. Regulating FOXS1 expression, whether upregulating or downregulating it, correspondingly enhanced or inhibited the growth, migration, and invasion capabilities of PCa cells. Mechanistically, we detected a direct interaction between FOXS1 and HILPDA, resulting in the pathway activation of FAK/PI3K/AKT and facilitation EMT in PCa cells. FOXS1 collaborates with HILPDA to initiate EMT, thereby facilitating the PCa progression through the FAK/PI3K/AKT pathway activation.

show abstract

Section: Discussionmentioning

confidence: 99%

FOXS1 acts as an oncogene and induces EMT through FAK/PI3K/AKT pathway by upregulating HILPDA in prostate cancer

Ren,

Wang,

et al. 2024

The FASEB Journal

View full text Add to dashboard Cite

show abstract

“…CHMP4C has been shown to be up-regulated in a variety of tumors and is related to malignant behavior. CHMP4C as a model gene for pyroptosis was more closely associated with prostate cancer prognosis implying prognostic value of CHMP4C in prostate cancer ( 14 ). High enrichment of CHMP4C in the urine of patients with high Gleason score prostate cancer suggested the potential of CHMP4C as a novel diagnostic marker for prostate cancer ( 15 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, the role of CHMP4C in prostate cancer is rarely mentioned. Previous studies have shown that CHMP4C is abundantly expressed as a component of extracellular vesicles in patients with high Gleason scores and as a novel signature of pyroptosis that affects the prognosis of prostate cancer patients ( 14 ) ( 15 ). Therefore, further validation of CHMP4C expression in prostate cancer, and whether CHMP4C affects the biological behavior of prostate cancer and the regulatory pathways involved, will help us to identify new biomarkers and new therapeutic options.…”

Section: Introductionmentioning

confidence: 99%

CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy

et al. 2023

View full text Add to dashboard Cite

BackgroundCHMP4C is one of the charged multivesicular protein (CHMP), and is involved in the composition of the endosomal sorting complex required for transport III (ESCRT-III), facilitating the necessary separation of daughter cells. CHMP4C has been proposed to be involved in the progression of different carcinomas. However, the value of CHMP4C in prostate cancer has not yet been explored. Prostate cancer is the most frequently occurring malignancy among male and remains a leading cause of deaths in cancers. So far, clinical therapy of prostate cancer is more inclined to molecular classification and specific clinical treatment and research. Our study investigated the expression and clinical prognosis of CHMP4C and explored its potential regulatory mechanism in prostate cancer. The immune status of CHMP4C in prostate cancer and relative immunotherapy were then analyzed in our study. Based on CHMP4C expression, a new subtype of prostate cancer was established for precision treatment.MethodsWe studied the expression of CHMP4C and relative clinical outcome using the online databases TIMER, GEPIA2, UALCAN, and multiple R packages. Meanwhile, the biological function, immune microenvironment and immunotherapy value of CHMP4C in prostate cancer were further explored on the R software platform with different R packages. Then we performed qRT-PCR, Western Blotting, transwell, CCK8, wound healing assay, colony formation assay and immunohistochemistry to verify the expression of CHMP4C, carcinogenesis and potential regulatory mechanisms in prostate cancer.ResultsWe found that the expression of CHMP4C is significant in prostate cancer and the high expression of CHMP4C represents a poor clinical prognosis and malignant progression of prostate cancer. In subsequent vitro validation, CHMP4C promoted the malignant biological behavior of prostate cancer cell lines by adjusting the cell cycle. Based on CHMP4C expression, we established two new subtypes of prostate cancer and found that low CHMP4C expression has a better immune response while high CHMP4C expression was more sensitive to paclitaxel and 5-fluorouracil. Above findings revealed a new diagnostic marker for prostate cancer and facilitated the subsequent precise treatment of prostate cancer.

show abstract

“…The key genes which may involve in the process of pyroptosis were obtained from the Molecular Signatures Database (MSigDB) [ 19 ] and the previous pyroptosis-related research [ 20 ]. After removing overlapping genes, 52 pyroptosis genes were included ( Supplementary Table 2 ).…”

Section: Methodsmentioning

confidence: 99%

Integrated analysis of bulk RNA-seq and single-cell RNA-seq reveals the function of pyrocytosis in the pathogenesis of abdominal aortic aneurysm

Zhao,

Cang,

Liu

et al. 2023

Aging

View full text Add to dashboard Cite

Pyrocytosis is involved in the development of abdominal aortic aneurysm (AAA), we explored the pyrocytosis-related hub genes in AAA and conducted a diagnostic model based on the pyrocytosis-related genes score (PRGs). A total of 2 bulk RNA-seq (GSE57691 and GSE47472) datasets and pyrocytosis-related genes were integrated to obtain 24 pyrocytosis-related different expression genes (DEGs). The LASSO Cox regression analysis was conducted to filter out 7 genes and further establish the nomogram signature based on the PRGs that exhibited a good diagnosis value. Weighted gene co-expression network analysis (WGCNA) established 14 gene modules and further identified 6 hub genes which were involved in the regulatory process of pyrocytosis in AAA. At the single cell level, we further identified 3 immune cells were highly associated with the pyrocytosis process in AAA. Finally, the cell-cell communication demonstrated that fibroblasts and endothelial cells and myeloid cells maintained close communications. Here, we identified the dysfunctional expressed pyrocytosis-related genes and immune cells in AAA, which provide a comprehensive understanding of the pathogenesis of AAA.

show abstract

A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients

Cited by 9 publications

References 67 publications

FOXS1 acts as an oncogene and induces EMT through FAK/PI3K/AKT pathway by upregulating HILPDA in prostate cancer

FOXS1 acts as an oncogene and induces EMT through FAK/PI3K/AKT pathway by upregulating HILPDA in prostate cancer

CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy

Integrated analysis of bulk RNA-seq and single-cell RNA-seq reveals the function of pyrocytosis in the pathogenesis of abdominal aortic aneurysm

Contact Info

Product

Resources

About